STOCK TITAN

WuXi AppTec Completes Acquisition of OXGENE to Further Strengthen Cell and Gene Therapy Service Offerings for Global Customers

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Rhea-AI Summary

WuXi AppTec has successfully completed its acquisition of OXGENE, a UK-based contract research organization specializing in gene therapy technologies. This acquisition enhances WuXi AppTec's capabilities in offering comprehensive support for cell and gene therapy development. OXGENE will operate as a wholly-owned subsidiary under WuXi Advanced Therapies and will be WuXi ATU's first facility in Europe, allowing for accelerated service offerings and reduced costs in viral vector manufacturing. The strategic move aims to improve accessibility and effectiveness of advanced therapies globally.

Positive
  • Acquisition enhances WuXi AppTec's service offerings in cell and gene therapy.
  • OXGENE's innovative TESSA technology simplifies viral vector manufacturing and reduces costs.
  • OXGENE will accelerate WuXi ATU's growth by becoming its first European facility.
Negative
  • None.

PHILADELPHIA and OXFORD, March 2, 2021 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the acquisition of OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable gene therapy technologies. This acquisition enables WuXi AppTec to offer its customers end-to-end support in the creation and development of cutting-edge cell and gene therapies for patients in need worldwide.

OXGENE will become a fully-owned subsidiary of WuXi Advanced Therapies (WuXi ATU), WuXi AppTec's cell and gene therapy Contract Testing, Development and Manufacturing Organization (CTDMO) business unit. WuXi ATU's integrated platforms transform the development, testing, manufacturing, and commercialization of cell and gene therapy products and accelerate their time to market. OXGENE, which will retain its name, will be WuXi ATU's first facility in Europe and will further enhance these industry-leading capabilities.

Since its founding in 2011, OXGENE has offered discovery and biomanufacturing solutions to the cell and gene therapy industries through novel technologies and contract research solutions. It also provides manufacturing systems that deliver exceptional scalability. OXGENE's novel TESSA technology for adeno-associated viral (AAV) manufacturing and XLenti stable solutions for lentiviral manufacturing simplify cell and gene therapy manufacturing while significantly reducing costs.

"OXGENE is proud to have invented a range of next-generation platforms that address the complexities of viral vector manufacturing for gene and cell therapies," said Dr. Ryan Cawood, Founder and Chief Executive Officer of OXGENE. "We are excited to join the team at WuXi ATU and to work together to scale up our technologies as a combined business, which will strengthen and broaden our service offerings for customers, improving by orders of magnitude the scale and cost of bringing cell and gene therapies to market. The benefits will be significant for the industry and for patients worldwide."

"We are delighted to welcome OXGENE to WuXi ATU," said Dr. David Chang, Chief Executive Officer of WuXi ATU. "By combining WuXi ATU's world-class cell and gene therapy CTDMO platform with OXGENE's innovative capabilities, we will be able to provide transformative solutions for our customers. This business combination represents a significant step in our ongoing effort to enable our customers and partners worldwide to deliver more effective and accessible advanced therapies to patients globally."

About OXGENE

OXGENE provides end-to-end contract services to cell and gene therapy companies seeking to discover, develop, manufacture and test innovative drug candidates at scale for global commercialization. OXGENE provides rapid, cost-effective services through proprietary technology and automation platforms for molecular discovery and by integrating the full suite of technologies needed for cell and gene therapy manufacturing. OXGENE is known for its expertise in designing DNA sequences, optimizing expression of proteins, developing cell lines, and improving viral delivery systems. For more information, please visit www.oxgene.com

About WuXi Advanced Therapies

As the advanced therapies business unit of WuXi AppTec, WuXi Advanced Therapies (WuXi ATU) is a Contract Testing, Development and Manufacturing Organization (CTDMO) that offers integrated platforms to transform the development, testing, manufacturing, and commercialization of cell, gene, and other advanced biopharmaceuticals. Our services and solutions accelerate time to market and support customer programs around the world. For more information, please visit www.advancedtherapies.com

About WuXi AppTec

WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps its partners improve the productivity of advancing healthcare products through cost-effective and efficient, socially responsible and sustainable solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec's open-access platform is enabling more than 4,100 collaborators from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated." Please visit: www.wuxiapptec.com

Cision View original content:http://www.prnewswire.com/news-releases/wuxi-apptec-completes-acquisition-of-oxgene-to-further-strengthen-cell-and-gene-therapy-service-offerings-for-global-customers-301238000.html

SOURCE WuXi AppTec

FAQ

What strategic advantages does WuXi AppTec gain from acquiring OXGENE?

WuXi AppTec gains enhanced capabilities in cell and gene therapy development, enabling comprehensive support and reducing costs in viral vector manufacturing.

What is the expected impact of the OXGENE acquisition on WuXi AppTec's operations?

The acquisition is expected to accelerate WuXi ATU's service offerings and improve the scalability and cost-effectiveness of advanced therapies.

When was the acquisition of OXGENE by WuXi AppTec completed?

The acquisition was completed on March 2, 2021.

What will be the role of OXGENE after the acquisition?

OXGENE will operate as a wholly-owned subsidiary of WuXi ATU, focusing on providing end-to-end solutions in gene therapy technologies.

How does OXGENE's technology contribute to WuXi AppTec's offerings?

OXGENE's TESSA technology aids in simplifying and scaling up the manufacturing processes of viral vectors, which enhances WuXi AppTec's capabilities in advanced therapies.

WUXI APPTEC CO UNSP/ADR

OTC:WUXAY

WUXAY Rankings

WUXAY Latest News

WUXAY Stock Data

20.80B
2.50B
Diagnostics & Research
Healthcare
Link
United States of America
Shanghai